Single-Domain Antibody Platforms Market - Scope of Report
As per the International Federation of Pharmaceutical Manufacturers & Associations, out of the total expenditure on drug discovery, 25% is spent on preclinical testing. Implementation of single-domain antibodies for drug discovery saves money and shortens the very lengthy process, contributing to higher demand in the single-domain antibody platforms market. For instance, in 2017, Sanofi (Ablynx N.V.) announced that it had completed the preparation of a pre-clinical package for a novel Nanobody® (ALX-1141) in osteoarthritis
Single-domain antibodies are highly successful against and potent inhibitors of viral infections, including hepatitis C virus (HCV), influenza viruses, HIV-1, and enteric viruses. According to TI Pharma and the European Trade Association, research investment for drug discovery has grown 5.2 times in the U.S. and 3.3 in Europe from the past two decades. With advancements in pharmaceutical therapies such as personalized therapies and increasing medical research to discover novel innovative drugs, demand for advanced methods of preclinical testing has witnessed an upsurge. Such factors will result in rapid expansion of the single-domain antibody platforms market size, which is projected to be 3X over the next ten years.
Find Out More about the Report Coverage
- Creative BioLabs A
- Synbio Technologies
- ProSci Incorporated
- BioCat GmbH
- Antibody Design Labs
- Oak BioSciences, Inc.
- Rockland Immunochemicals, Inc
- Hybrigenics Services
- NeoClone Biotechnology International LLC
- Kaneka Eurogentec S.A
Single-Domain Antibody Platforms Market Trends
Approval & Launch of Novel Immunotherapies with Help of Single-Domain Antibodies: Leading industry players are focusing on development and launch of novel immunotherapies with the help of single-domain antibodies to treat various types of cancers and infectious diseases. This accelerated availability of single-domain antibodies for Immunotherapeutics is expected to boost the growth of the single-domain antibody platforms market over the coming years. For industry players, ROI is high for cancer therapeutics, owing to right of market exclusivity, high selling prices, and government incentives for such novel treatment options.
- In April 2019, there was a collaboration between REMD Biotherapeutics Inc. & GenScript Biotech for development of several bispecific antibodies. According to the agreement, GenScript will allow REMD to use its SMAB (Single-Domain Antibody fused to Monoclonal Ab) platform, a bispecific antibody platform, to develop novel tumor immunotherapy drugs.
- In July 2016, ProSci Incorporated announced the release of multiple single-domain antibodies against the human programmed death ligand 1 (PD-L1).
Focus on Offering Single-Domain Antibody Platform Services in Developing Regions: Although the single-domain antibody platform services market has several leading players as well as multiple domestic companies, there are a limited number of companies with complete focus on being a provider of single-domain antibody platform services. Different manufacturers have different specializations and service offerings, with most large companies combining research products, biologics, recombinant proteins, and customized antibody products.
Manufacturers having focus on single-domain antibody platforms ensure better quality of service and an established distribution network that can ensure product availability around the globe. R&D spending on life sciences is among the largest, and is expected to grow at a stable rate over the next several years. Moreover, focus on emerging economies and increasing R&D investments will boost the growth of the single-domain antibody platforms market. Developing economies such as China, India, and Brazil have ample professional manpower and skilled labour at affordable costs, thereby increasing the scope for outsourcing biotech projects.
Research Collaboration, Product Licensing, Acquisition, and Expansion in Emerging Economies: Product or technology licensing and acquisition offers great opportunities to strengthen market positioning. In addition, these strategies provide significant growth opportunities in terms of early market entry and product/technology differentiation.
Increasing investments in the healthcare sector in developing economies are anticipated to boost demand for single-domain antibody therapeutics in developing regions. Higher cancer patient pool and increasing per capita income can provide significant market opportunities in the future.
- For instance, in April 2019, GenScript allowed REMD Biotherapeutics Inc to use its single-domain antibody platform, to produce bispecific antibodies during drugs development for novel tumor immunotherapy.
Specialized developers are gaining significant traction in the single-domain antibody platforms market. Leading industry players collaborate actively with innovative startups and academic research centers. These collaborations provide long-term, high-ROI opportunities.
- For instance, in March 2017, Ablynx N.V. and Merck KGaA entered into a collaboration to check the efficacy of the bispecific anti-IL-17A/F Nanobody® (M1095; ALX-0761) in patients with chronic plaque psoriasis.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Regional Outlook of Single-Domain Antibody Platforms Market
North America holds more than 35% the single-domain antibody platforms market share, due to increased adoption of biological services by researchers for their projects to reduce time and errors. Moreover, single-domain antibodies are effective against infectious disease. Europe holds the second-largest share in the single-domain antibody platforms market, due to awareness about single-domain antibodies in immune therapy in the region. Asia Pacific and the Middle East & Africa are expected to hold lucrative market shares. Increased R&D investments, collaborative research, and government initiatives are expected to further support the growth of the single-domain antibody platforms market in these regions.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
COVID-19 Impact on Single-Domain Antibody Platforms Market
The global outbreak of COVID-19 has had a positive impact on the single-domain antibody platforms market. There is increasing need for antiviral antibodies in the development of new drugs and treatment options for the new coronavirus. Single-domain antibodies have confirmed their potential in treating coronavirus to some extent. However, in the 1st half of 2020, the pandemic created a short term-decline in the manufacturing and sales of single-domain antibodies, as a result of shutdowns and less production at manufacturing facilities.
Explore Persistence Market Research’s expertise in promulgation of the business !
An analysis of the single-domain antibody platforms market has brought our analysts to a conclusion that, the market is growing at a remarkable pace. Currently, the bispecific single-domain antibody is the most lucrative segment for leading service providers, and, as such, this segment dominates the global single-domain antibody platforms market by platform type in term of growth. Currently North America holds more than half of the revenue share due to increasing drug development activities in the region. Developing countries such as India, Brazil, China, and Thailand are expected to offer lucrative opportunities for players in the single-domain antibody platforms market, owing to increasing awareness and initiatives by local governments for research & development.